Proshares Ultra Nasd BiotechBIBETF
13F holders, Q2 2025 (June 30)17holders −6
1new positions
6sold out
$45.80avg. 13F price*
At the end of Q2 2025, 17 institutions reported holding Proshares Ultra Nasd Biotech (BIB) in their 13F filings, down 6 from Q1 2025. 1 opened new positions and 6 sold out. The largest holders were Chase Investment Counsel Corp. ($411K), Westwood Wealth Management ($366K) and Susquehanna International Group, LLP ($291K).
- Company
- Proshares Ultra Nasd Biotech
- CUSIP
- 74347R214
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $32K |
| Exits | 6 | $1.7M |
All 13F filers, Q1 2025 → Q2 2025: 841 shares bought and 49,376 shares sold, net −48,535 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 17 holders
| Chase Investment Counsel Corp. | 0.13% | No change | 8,980 | $411K |
| Westwood Wealth Management | 0.12% | No change | 8,000 | $366K |
| Susquehanna International Group, LLP | 0.00% | Reduce -54.3% | 6,342 | $291K |
| Capital Investment Advisors, LLC | 0.01% | Reduce -9.8% | 6,296 | $288K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -41.4% | 2,600 | $119K |
| Toth Financial Advisory Corp. | 0.01% | Reduce -82.3% | 997 | $46K |
| Franklin Resources Inc. | 0.00% | New | 696 | $32K |
| Park Square Financial Group, LLC | 0.01% | No change | 316 | $14K |
| MAI Capital Management | 0.00% | No change | 250 | $11K |
| Garde Capital, Inc. | 0.00% | No change | 236 | $11K |
| Harel Insurance Investments & Financial Services Ltd. | 0.00% | No change | 198 | $9K |
| Truvestments Capital LLC | 0.00% | No change | 125 | $6K |
| UBS Group AG | 0.00% | Add +12300.0% | 124 | $6K |
| Morgan Stanley | 0.00% | Add +33.3% | 88 | $4K |
| Whittier Trust Co. | 0.00% | No change | 75 | $3K |
| Qube Research & Technologies Ltd | 0.00% | No change | 53 | $2K |
| Chilton Capital Management LLC | 0.00% | No change | 39 | $2K |
"% of holder's portfolio" is BIB's weight in each manager's 13F, not the share of Proshares Ultra Nasd Biotech the manager owns.